Top

Published in:

06-12-2022 | Fatty Liver | Letter to the Editor

MAFLD: perceived stigma—a single-center Mexican patient survey

Authors: Nahum Méndez-Sánchez, Shreya C. Pal, Eduardo Fassio, Javier Díaz-Ferrer, Jorge Alberto Prado-Robles

Published in: Hepatology International | Issue 2/2023

Excerpt

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) [formerly known as non-alcoholic fatty liver disease (NAFLD)] is a highly prevalent disease that affects around 30% of the global population. …

Available only for authorised users

Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039CrossRefPubMed

Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390CrossRefPubMed

Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American association for the study of the liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65–72. https://doi.org/10.1016/S2468-1253(20)30340-XCrossRefPubMed

Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol. 2021;74(4):972–974. https://doi.org/10.1016/j.jhep.2020.10.015CrossRefPubMed

Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–1198. https://doi.org/10.1002/hep.31420CrossRefPubMed

Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88–97CrossRefPubMed

Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128. https://doi.org/10.1111/HEPR.13685CrossRefPubMed

Title: MAFLD: perceived stigma—a single-center Mexican patient survey
Authors: Nahum Méndez-Sánchez
Shreya C. Pal
Eduardo Fassio
Javier Díaz-Ferrer
Jorge Alberto Prado-Robles
Publication date: 06-12-2022
Publisher: Springer India
Keyword: Fatty Liver
Published in: Hepatology International / Issue 2/2023
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-022-10448-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2023

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis

Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications

Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies

Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury

Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials